title: [Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer].
abstract: OBJECTIVE
  Recent studies have revealed that TGF-beta/Smads signaling pathway plays a pivotal role in the oncogenesis and development of malignant tumors, and may closely relate to the biological behaviors of some malignant tumors, such as gastric carcinoma. This study was to investigate the expression of transforming growth factor-beta receptor II (TGF-betaRII), Smad4 and Smad7 proteins in gastric carcinoma, and explore their correlations to clinicopathologic characteristics and prognosis of gastric carcinoma.
  
  
  METHODS
  The expression of TGF-betaRII, Smad4, and Smad7 was detected by SABC immunohistochemistry and tissue microarray which containing 200 specimens of primary human gastric carcinoma and 56 specimens of adjacent gastric tissue.
  
  
  RESULTS
  The positive rates of TGF-betaRII, Smad4, and Smad7 in gastric carcinomas were 25.5%, 67.0%, and 47.0%, respectively. TGF-betaRII expression was related with depth of invasion, lymph node metastasis, tumor differentiation, and Lauren classification (Chi2=6.214, Chi2=11.308, Chi2=14.633, and Chi2=8.216, respectively, all P<0.05). Smad4 expression was related with tumor differentiation and Lauren classification (Chi2=16.162 and Chi2=13.100, all P<0.05). Smad7 expression was related with tumor differentiation and Lauren classification (Chi2=4.710 and Chi2=5.297, all P<0.05). Smad4 expression was positively correlated to TGF-betaRIIexpression (r =0.191, P=0.007). Smad4 expression was related with patients' survival (Chi2=4.090, P=0.043).
  
  
  CONCLUSIONS
  Abnormal expression of TGF-Smad signaling pathway proteins occurs in gastric carcinoma. Smad4-positive gastric carcinoma patients have better prognosis than Smad4-negative patients.
authors.affiliation: Department of Gastroenterology, The First Hospital, Lanzhou University, Lanzhou, Gansu, China. yongningzhou@sina.com.cn
authors.forename: Bin
authors.initials: B
authors.lastname: Lu
authors.forename: Yong-Ning
authors.initials: YN
authors.lastname: Zhou
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Zheng-Qi
authors.initials: ZQ
authors.lastname: Wu
authors.forename: Zhi-Yi
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Ji
authors.forename: Qing-Hong
authors.initials: QH
authors.lastname: Guo
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D002454:Cell Differentiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism*; D015398:Signal Transduction; D051901:Smad4 Protein / Q000378:metabolism*; D051906:Smad7 Protein / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D015996:Survival Rate
chemical_list: D018125:Receptors, Transforming Growth Factor beta; C497796:SMAD4 protein, human; C497806:SMAD7 protein, human; D051901:Smad4 Protein; D051906:Smad7 Protein; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II